Kestra Advisory Services, LLC Immuno Gen, Inc. Transaction History

Kestra Advisory Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$4.48 - $6.47 $31,162 - $45,005	-6,956 Reduced 30.59%	15,787 $75 Million
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $2,283 - $4,176	-725 Reduced 3.09%	22,743 $102,000
Q1 2022 Apr 26, 2022	BUY	$4.26 - $7.48 $12,716 - $22,327	2,985 Added 14.57%	23,468 $111,000
Q4 2021 Jan 20, 2022	SELL	$4.75 - $7.5 $21,983 - $34,710	-4,628 Reduced 18.43%	20,483 $151,000
Q3 2021 Oct 19, 2021	SELL	$5.02 - $6.59 $5,095 - $6,688	-1,015 Reduced 3.89%	25,111 $142,000
Q2 2021 Jul 28, 2021	SELL	$5.79 - $8.6 $10,723 - $15,927	-1,852 Reduced 6.62%	26,126 $172,000
Q1 2021 May 10, 2021	BUY	$6.5 - $10.53 $181,857 - $294,608	27,978 New	27,978 $226,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.